Zidesamtinib (NVL-520) for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 12 Nov 2021: Trial registered, NCT05118789
  2. 4 Jan 2022: Trial started, NCT05118789

The trials

NCT05118789: A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

State
Under way
Phase
Phase 1 and Phase 2
People
359 planned
Started
4 Jan 2022
Primary completion
31 Dec 2027
Arms
Phase 1 dose escalation, Cohort 2a, Cohort 2b, Cohort 2c, Cohort 2d, Cohort 2e
Results
None posted
  1. 12 Nov 2021: Trial registered
  2. 4 Jan 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.